Customize FZR3 Antibody

Description

Clarification of Terminology

FGFR3 Antibodies: These target Fibroblast Growth Factor Receptor 3, a receptor tyrosine kinase implicated in cancers (e.g., bladder cancer, multiple myeloma) and neuropathies. Research highlights include:
- Clinical Applications: FGFR3 antibodies like PRO-001 and bispecific variants inhibit oncogenic FGFR3 mutations in cancers .
- Neurological Disorders: Anti-FGFR3 antibodies are linked to autoimmune neuropathies, presenting with symptoms like paresthesia and gait instability .
- Structure: FGFR3 antibodies typically feature IgG isotypes with Fab and Fc regions for antigen binding and immune modulation .
Frizzled-3 (FZD3) Antibodies: A separate family of Wnt-signaling receptors. One search result describes a Human/Mouse Frizzled-3 APC-conjugated Antibody (Clone 169310) used in flow cytometry , but this is unrelated to "FZR3."

Potential Causes of Confusion

Typographical Errors: "FZR3" may be a misspelling of FGFR3 or FZD3. For example:
- FGFR3 antibodies are well-documented in cancer and neuropathy research .
- FZD3 antibodies target Wnt pathway receptors .
Unrecognized Targets: No peer-reviewed studies, patents, or commercial products reference "FZR3" as a validated biological target.

Suggested Alternatives

If the intended query relates to FGFR3 or FZD3 antibodies, below are key findings from the search results:

FGFR3 Antibody Research Highlights

Aspect	Details	Sources
Therapeutic Use	Bispecific FGFR3×FGFR3 antibodies inhibit oncogenic mutants (e.g., S249C) and fusion proteins.
Neurological Impact	Associated with sensorimotor neuropathies (painful paresthesia, gait instability).
Structural Features	IgG isotype with Fab domains for antigen binding and Fc regions for immune effector functions.
Clinical Trials	PRO-001 (anti-FGFR3) shows cytotoxicity in FGFR3-expressing myeloma cells.

FZD3 Antibody Example

Product	Application	Reactivity	Source
Human/Mouse Frizzled-3 APC	Flow cytometry (HEK293, D3 cell lines)	Membrane-associated

Product Specs

Buffer

Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4

Form

Liquid

Lead Time

Made-to-order (14-16 weeks)

Synonyms

FZR3 antibody; CCS52B antibody; CDH1-3 antibody; At5g13840 antibody; MAC12.21Protein FIZZY-RELATED 3 antibody; Cell cycle switch protein CCS52B antibody

Target Names

FZR3

Uniprot No.

Q8LPL5

Target Background

Function

FZR3 is an activator protein that regulates the ubiquitin ligase activity and substrate specificity of the anaphase promoting complex/cyclosome (APC/C).

Gene References Into Functions

CCS52B, a homolog of FZR3, plays a role in nematode feeding site generation. [CCS52B] PMID: 23518580

Database Links

KEGG: ath:AT5G13840

STRING: 3702.AT5G13840.1

UniGene: At.32010

Protein Families

WD repeat CDC20/Fizzy family

Q&A

FAQs on FGFR3 Antibody Research
(Note: Available research primarily focuses on FGFR3 antibodies. If referencing "FZR3" was intended as a distinct target, current literature provides limited direct evidence.)

Advanced Research Questions

How can conflicting data on FGFR3 antibody clinical associations be resolved?
- Key contradictions:
  
  Study FGFR3-Associated Phenotype Motor Involvement
  Sensorimotor neuropathy (41%) Distal weakness (40%)
  Pure sensory neuronopathy (82%) Rare (5%)
  Small/large fiber mix (50%) Mild distal weakness (43%)
- Resolution strategies:
  - Stratify patients by antibody titer (higher titers >10,000 correlate with motor symptoms) .
  - Perform nerve biopsies to differentiate demyelinating (41%) vs. axonal (50%) subtypes .
What methodological challenges arise in detecting FGFR3 antibodies in heterogeneous cohorts?
- Pre-analytical factors:
  - Serum storage in PBS + 50% glycerol prevents antibody degradation .
  - Avoid freeze-thaw cycles >3x to preserve epitope integrity .
- Assay limitations:
  - ELISA sensitivity drops in patients with concurrent IgM/IgA autoantibodies .
  - False negatives in pure small-fiber neuropathy require skin biopsy confirmation (intraepidermal nerve fiber density <5/mm) .

Study	FGFR3-Associated Phenotype	Motor Involvement
	Sensorimotor neuropathy (41%)	Distal weakness (40%)
	Pure sensory neuronopathy (82%)	Rare (5%)
	Small/large fiber mix (50%)	Mild distal weakness (43%)

Technical Considerations

How do Fc receptor polymorphisms impact FGFR3 antibody therapeutic responses?
- Mechanism: FcγRIIIa-V158 alleles enhance IVIg efficacy via increased ADCC (OR: 3.2, 95% CI: 1.4–7.1) .
- Design implications:
  - Use IgG1 isotype for IVIg to maximize FcγRIIIa binding .
  - Monitor for accelerated clearance in patients with FcμR polymorphisms .
What biomarkers predict immunotherapy response in FGFR3 antibody-associated neuropathies?
- Predictors:
  - Acute symptom onset (OR: 4.8 for IVIg response) .
  - Elevated CSF protein (>45 mg/dL) correlates with nerve biopsy demyelination (p=0.02) .
- Monitoring: Serial nerve conduction studies (NCS) at 0/6/12 months to track amplitude improvements (≥50% = favorable) .

Quick Inquiry

Personal Email Detected

Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *

Name*

Email*

Phone

Country

Source

Quantity&Size*

Product Name

Message

FZR3 Antibody